(NASDAQ: QNCX) Quince Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.
Quince Therapeutics's earnings in 2026 is -$33,037,000.On average, 4 Wall Street analysts forecast QNCX's earnings for 2026 to be -$9,294,356, with the lowest QNCX earnings forecast at -$12,188,715, and the highest QNCX earnings forecast at -$6,076,101. On average, 4 Wall Street analysts forecast QNCX's earnings for 2027 to be -$8,716,576, with the lowest QNCX earnings forecast at -$13,075,313, and the highest QNCX earnings forecast at -$3,936,629.
In 2028, QNCX is forecast to generate $914,472 in earnings, with the lowest earnings forecast at $878,610 and the highest earnings forecast at $941,368.